SYNCONA LIMITED ORD NPV overview

LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that, in connection with Syncona’s acquisition of Freeline by way of a scheme of arrangement (the “Scheme”), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the “Scheme Circular”) has been delivered to the Registrar of Companies....

LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that Freeline’s shareholders have approved the proposal for Bidco 1354 Limited (“Bidco”), a wholly owned subsidiary of Syncona Portfolio Limited (“Syncona Portfolio”), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share (“ADS”) in cash (the “Acquisition”). As...

Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support...

Syncona Limited - Issue of shares pursuant to the Long Term Incentive Plan PR Newswire London, August 13 Syncona Limited Issue of shares pursuant to the Long Term Incentive Plan 13 August 2018 Syncona Limited (the "Company") today announces that a total of 20,836 new ordinary shares will be issued in satisfaction of realisations under the Company’s Long Term Incentive Plan. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In...

Syncona Limited - Nightstar reports Q2 2018 financial results PR Newswire London, August 13 Syncona Limited Nightstar reports Q2 2018 financial results 13 August 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, notes the announcement that its portfolio company, Nightstar Therapeutics Plc (NASDAQ: NITE) (Nightstar), reported its Second Quarter 2018 Financial Results today, 13 August 2018 . The announcement can be accessed on...

Syncona Limited - Syncona Limited Quarterly Update PR Newswire London, August 8 Syncona Limited Quarterly Update 9 August 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today issues its quarterly update covering the period from 1 April 2018 to 30 June 2018 . Financial and Operational highlights for the three months ending 30 June Net assets increased to £1,283.2 million, 193.1p per share[1], a total return of 23.0 per cent[2]...

Syncona Limited - PDMR Dealing PR Newswire London, August 2 Syncona Limited Notification of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs") and Connected Persons 2 August 2018 1. Details of PDMR / person closely associated with them ("PCA") a) Name Martin Murphy b) Position / status Chief Executive Officer, SIML c) Initial notification / amendment Initial Notification 2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each...

Syncona Limited - Results of AGM PR Newswire London, July 31 Syncona Limited Result of Annual General Meeting 31 July 2018 At the Annual General Meeting (“AGM”) of the Company held today, all Resolutions as set out in the Notice of AGM dated 27 June 2018 sent to shareholders of the Company (the “Notice”) were duly passed. Resolutions 1 to 13 were proposed as ordinary resolutions. Only shareholders who were “Independent Shareholders” as such term is defined in the Notice were entitled...